<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="464">
  <stage>Registered</stage>
  <submitdate>8/09/2005</submitdate>
  <approvaldate>11/11/2005</approvaldate>
  <actrnumber>ACTRN12605000730606</actrnumber>
  <trial_identification>
    <studytitle>The effects of sleep deprivation and dexamphetamine on driving, neuropsychological function and brain activity in professional drivers</studytitle>
    <scientifictitle>The effects of sleep deprivation and dexamphetamine on driving, neuropsychological function and brain activity in professional drivers</scientifictitle>
    <utrn />
    <trialacronym>SPEED SLEEP</trialacronym>
    <secondaryid>nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Sleep deprivation</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A group of current amphetamine users will undergo 4 sessions, 2 sleep deprived and 2 at rest, each with a placebo and dexamphetamine condition. 
A group of non-users will undergo 2 sessions, 1 sleep deprived and 1 at rest.</interventions>
    <comparator>no sleep deprivation
placebo (cellulose capsules)</comparator>
    <control>Placebo</control>
    <interventioncode>Behaviour</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>lane deviation on a simulated driving task</outcome>
      <timepoint>Users group: primary outcome measures are assessed at rest, following 27-h sleep deprivation, dexamphetamine administration, and following sleep deprivation and dexamphetamine admin.
Non-users group: measures are assessed at rest and  following 27-h sleep deprivation.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Driving simulation</outcome>
      <timepoint>27-hours of sleep derpviation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Psychomotor vigilance task</outcome>
      <timepoint>27-hours of sleep derpviation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PERCLOS - slow eye closure</outcome>
      <timepoint>27-hours of sleep derpviation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>(Control group): Curent drivers license. Not used amphetamine within last 10 years. (Users group): Current drivers license. Currently use amphetamine.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>History of cardiovascular disease, hypertension, epilepsy, diabetes, psychiatric illness; heavy Smokers; 5 or more caffienated beverages per day; Visual impairment that does not correct with glasses; English not first language.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Educational / counselling / training</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>randomised codes, concealed until completion of the study</concealment>
    <sequence>computerised, dexamphetamine not administered to drug-naive group</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/06/2004</anticipatedstartdate>
    <actualstartdate>1/06/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate>22/06/2007</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>IBAS</primarysponsorname>
    <primarysponsoraddress>Austin Health
Studley Rd
Heidelberg VIC 3084</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Institute for Breathing and Sleep</fundingname>
      <fundingaddress>Austin Health
145 Studley Rd, 
Heidelberg VIC 3084</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Austin Health Medical Research Fund</fundingname>
      <fundingaddress>Austin Health
145 Studley Rd, 
Heidelberg VIC 3084</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>AHMRF</sponsorname>
      <sponsoraddress>Austin Health
Studley Rd
Heidelberg VIC 3084</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study reported on driving and vigilance after 27-h of sleep deprivation in professional drivers. The study is completed.</summary>
    <trialwebsite />
    <publication>Jackson ML, Croft RJ, Papafotiou K, Pierce RJ, Kennedy GA, Crewther D, Howard M. (2008). The effect of acute sleep deprivation on visual evoked potentials in professional drivers. Sleep 31(9): 1261-1269. 

Jackson ML, Hughes ME, Croft RJ, Howard ME, Owens K, Pierce RJ, Kennedy GA, Crewther D, Johnston P. (2011). The effect of sleep deprivation on BOLD activity elicited by a divided attention task. Brain Imaging and Behavior 5(2): 97-108.


Jackson ML, Croft RJ, Kennedy GA, Owens K, Howard ME. (2013). Cognitive components of simulated driving performance: Sleep loss effects and predictors. Accident Analysis and Prevention 50: 438-444. 

7/12/2005	The effects of sleep deprivation on visual evoked potentials and peripheral vision in professional drivers  preliminary results. Australasian Society for Psychophysiology conference, Wollongong.  

7/12/2007	The effects of acute sleep deprivation on a cross-modal divided attention task: a functional neuroimaging study. Australasian Society for Psychophysiology, Brisbane. 

11/2/2009	The effects of sleep deprivation on driving-related performance in Australian professional drivers. Washington State University, Spokane, Washington, USA. Invited lecture.

13/8/2008	The effects of acute sleep deprivation on a cross-modal divided attention task: a functional neuroimaging study. European Sleep Research Society conference, Glasgow, Scotland.

12/7/2008	The effects of sleep deprivation and d-amphetamine on driving-related performance in Australian professional drivers. Royal Brompton Hospital, London, UK.  

27/8/2007	The effect of 27-hours sleep deprivation on simulated driving performance &amp; cognition in professional drivers. International Congress for Alcohol Drugs and Traffic Safety, Seattle, WA, USA.

</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Swinburne University</ethicname>
      <ethicaddress />
      <ethicapprovaldate>26/03/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Melinda Jackson</name>
      <address>Immunology B Ambulatory Care (IBAS)Austin Health
Bowen Centre
Studley Rd
Heidelberg VIC 3084</address>
      <phone>+61 3 94963977</phone>
      <fax />
      <email>melinda.jackson@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Melinda Jackson</name>
      <address>Institute for Breathing and Sleep
Austin Health
Studley Rd
Heidelberg VIC 3084</address>
      <phone>+61 3 94963977</phone>
      <fax>+61 3 94963875</fax>
      <email>melinda.jackson@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Melinda Jackson</name>
      <address>Institute for Breathing and Sleep
Austin Health
Studley Rd
Heidelberg VIC 3084</address>
      <phone>+61390356129</phone>
      <fax />
      <email>melinda.jackson@austin.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>